Vultaggio Vincent's Form 4 filing
Zentalis Pharmaceuticals, Inc. (ZNTL) · filed Feb 10, 2026
- Accession no.
- 0002018766-26-000006
- Filed
- Feb 10, 2026
- Trade date
- Feb 6-10, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $97.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vultaggio VincentCIK 0002018766 | Officer (PAO and PFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | Common Stock | SSaleDisposed | −29,951 | $2.43 | −$72,780.93 | 156,779 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −3,379 | $2.39 | −$8,075.81 | 153,400 | Direct | |
| Feb 10, 2026 | Common Stock | SSaleDisposed | −6,894 | $2.42 | −$16,683.48 | 146,506 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.